Free tool
FAERS Monitor: Cuvposa
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022571 or its brand name (Cuvposa, Glycopyrrolate). Reports on generic versions are filed under their own applications.
Reports
5,640
Serious
4,741
84% of reports
Hospitalization
2,392
Death reported
679
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,058
- asthma853
- wheezing719
- cough670
- pneumonia585
- drug ineffective448
- off label use387
- fatigue376
- malaise365
- chronic obstructive pulmonary disease361
- productive cough350
- chest discomfort337
- nausea337
- condition aggravated325
- therapeutic product effect incomplete317
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 14 |
| 2006 | 16 |
| 2007 | 30 |
| 2008 | 29 |
| 2009 | 46 |
| 2010 | 62 |
| 2011 | 74 |
| 2012 | 88 |
| 2013 | 71 |
| 2014 | 128 |
| 2015 | 148 |
| 2016 | 230 |
| 2017 | 434 |
| 2018 | 300 |
| 2019 | 325 |
| 2020 | 289 |
| 2021 | 462 |
| 2022 | 632 |
| 2023 | 573 |
| 2024 | 611 |
| 2025 | 672 |
| 2026 | 393 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,519 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wheezingSignal | 719 | 45.8 | 42.7 | 31,139 |
| asthmaSignal | 853 | 28.4 | 26.6 | 22,433 |
| productive coughSignal | 350 | 27.5 | 24.9 | 8,879 |
| chronic obstructive pulmonary diseaseSignal | 361 | 26.0 | 23.5 | 8,605 |
| therapeutic product effect incompleteSignal | 317 | 16.7 | 15.0 | 4,654 |
| chest discomfortSignal | 337 | 12.3 | 11.1 | 3,496 |
| coughSignal | 670 | 8.9 | 8.3 | 4,762 |
| dyspnoeaSignal | 1,058 | 7.0 | 6.6 | 5,555 |
| pneumoniaSignal | 585 | 6.7 | 6.2 | 2,898 |
| condition aggravatedSignal | 325 | 4.0 | 3.6 | 735 |
| malaiseSignal | 365 | 3.1 | 2.8 | 529 |
| fatigue | 376 | 1.8 | 1.6 | 138 |
| off label use | 387 | 1.6 | 1.5 | 102 |
| nausea | 337 | 1.6 | 1.4 | 76 |
| drug ineffective | 448 | 1.3 | 1.2 | 27 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.